-
公开(公告)号:JPH11147867A
公开(公告)日:1999-06-02
申请号:JP36552997
申请日:1997-12-22
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS ULRICH DR , PEYMAN ANUSCHIRWAN , KNOLLE JOCHEN DR , RUXER JEAN-MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN-MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: C07D239/00 , A61K31/155 , A61K31/16 , A61K31/18 , A61K31/33 , A61K31/395 , A61K31/415 , A61K31/4184 , A61K31/47 , A61K31/472 , A61K31/55 , A61K38/04 , A61P9/00 , A61P19/08 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C279/20 , C07C279/24 , C07C311/64 , C07C313/30 , C07C327/00 , C07D217/24 , C07D233/04 , C07D235/16 , C07D243/06 , C07D253/06 , C07D253/08 , C07D263/52 , C07D267/08 , C07D277/60 , C07D471/02 , C07D471/04 , C07D487/04 , C07K5/04
Abstract: PROBLEM TO BE SOLVED: To obtain a new compound useful as a vitronectin receptor antagonist used as an agent for inhibiting the bone resorption by osteoclasts, an agent for inhibiting the growth or metastasis of tumors or an anti-inflammatory agent and further used for treating and preventing cardiovascular diseases, neuropathy, retinopathy or the like. SOLUTION: The compound of the formula: A-B-D-E-F-G [G is A1 or the like; A1 is R R N-C(=NR )NR C(O) or the like; B is a direct bond or the like; D and F are each a direct bond or the like; E is a template selected from a series of fibrinogen receptor antagonists; G is a group of the formula; R and R are each H or the like; R to R are each H or the like; R is C(O)R or the like; R is OH or the like; (q) and (p) are each 0 or 1], The wherein F is C(O)NR , is obtained, for example, by condensing a compound of the formula: A-B-D-E-M (M is a hydroxycarbonyl or the like) with a compound of the formula: HNR -G.
-
2.
公开(公告)号:JPH1143476A
公开(公告)日:1999-02-16
申请号:JP19715497
申请日:1997-07-23
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , STILZ HANS ULRICH DR , GOURVEST JEAN-FRANCOIS DR , CARNIATO DENIS , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR , PITTI ROBERT MAURICE , BODARY SARAH CARHERINE DR
IPC: C07C229/04 , A61K31/155 , A61K31/197 , A61K31/27 , A61K31/415 , A61K31/445 , A61K31/505 , A61P9/00 , A61P13/02 , A61P15/00 , A61P19/00 , A61P19/08 , A61P19/10 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C251/02 , C07C279/20 , C07C333/00 , C07D233/48 , C07D233/54 , C07D239/16 , C07D239/72 , C07D239/84
Abstract: PROBLEM TO BE SOLVED: To obtain the subject new compound inhibiting the bone absorption of osteoclast and useful for bone diseases such as osteoporosis and hypercalcemia. SOLUTION: A compound of the formula: R -Y-A-B-D-E-F-G R is a (substituted) four to ten-membered ring, etc.; A is CO2 , etc.; B is a single direct bond, etc.; D, F are each O, etc.; E is a (substituted) aromatic ring system; G is a group of formula I [R is a 10-18C cycloalkyl, etc.; R is H, etc.; R is pyrazolyl, etc.; (q) is 0, 1]; Y is NR (R is H, etc.}. For example, a compound of formula II. The objective compound of the formula wherein F is C(O)NR is obtained e.g. by condensing a compound of the formula: R -Y-A-B-D-E-M (M is hydroxycarbonyl, etc.), with a compound of the formula: HNR -G. When orally administered as a medicine, the objective compound is preferably administered at a daily dose of 0.01-50 mg/kg.
-
公开(公告)号:JPH10182617A
公开(公告)日:1998-07-07
申请号:JP36552897
申请日:1997-12-22
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS-ULRICH DR , PEYMAN ANUSCHIRWAN DR , SCHEUNEMANN KARLHEINZ DR , RUXER JEAN-MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN-MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: C07D295/18 , A61K31/33 , A61K31/415 , A61K31/4184 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5355 , A61K31/536 , A61K31/5375 , A61K31/55 , A61K31/66 , A61P9/00 , A61P19/10 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D235/30 , C07D239/84 , C07D243/06 , C07D243/24 , C07D253/06 , C07D253/08 , C07D263/52 , C07D265/12 , C07D265/18 , C07D267/08 , C07D277/60 , C07D279/00 , C07D471/04 , C07D521/00 , C07F9/6561
Abstract: PROBLEM TO BE SOLVED: To obtain a new compound useful for bone diseases such as osteoporosis and chronic arthrorheumatism, capable of suppressing bone absorption by osteoclast. SOLUTION: This new compound is shown by the formula A-B-D-E-F-G A is a group of formula I (Y is an NR , O, etc.; R is H, a 1-10C alkyl, etc.; (q) is 0 or 1; a group of formula II is a five- to tenmembered cyclic base; B is a direct bond, a 1-8C alkanediyl, etc.; D and F are each a direct bond, a 1-8C alkanediyl, etc.; E is a template selected from fibrinogen receptor antagonists; G is a group of formula III [R to R are each H, F, OH, etc.; R is C(O)R (R is OH, a 1-8C alkoxy, etc.), C(S)R , etc.]} such as a human vitronectin receptor. The compound of the formula is obtained by condensing a compound of the formula A-B-D-E-M (M is hydroxycarbonyl, etc.) with a compound of the formula HNR k-G. For example, in the case of A-B is a ground of formula IV, a compound of formula V is reacted with a sulfonic acid of the formula Q-S(O)n -D-E-F-G or its derivative to give the objective compound.
-
公开(公告)号:CZ9704113A3
公开(公告)日:1998-07-15
申请号:CZ411397
申请日:1997-12-18
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS ULRICH DR , PEYMAN ANUSCHIRWAN DR , KNOLLE JOCHEN DR , RUXER JEAN-MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN-MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: C07D239/00 , A61K31/155 , A61K31/16 , A61K31/18 , A61K31/33 , A61K31/395 , A61K31/415 , A61K31/4184 , A61K31/47 , A61K31/472 , A61K31/55 , A61K38/04 , A61P9/00 , A61P19/08 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C279/20 , C07C279/24 , C07C311/64 , C07C313/30 , C07C327/00 , C07D217/24 , C07D233/04 , C07D235/16 , C07D243/06 , C07D253/06 , C07D253/08 , C07D263/52 , C07D267/08 , C07D277/60 , C07D471/02 , C07D471/04 , C07D487/04 , C07K5/04
CPC classification number: C07D487/04
-
公开(公告)号:CZ9704112A3
公开(公告)日:1998-07-15
申请号:CZ411297
申请日:1997-12-18
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS ULRICH DR , PEYMAN ANUSCHIRWAN DR , SCHEUNEMANN KARLHEINZ DR , RUXER JEAN-MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN-MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: C07D295/18 , A61K31/33 , A61K31/415 , A61K31/4184 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5355 , A61K31/536 , A61K31/5375 , A61K31/55 , A61K31/66 , A61P9/00 , A61P19/10 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D235/30 , C07D239/84 , C07D243/06 , C07D243/24 , C07D253/06 , C07D253/08 , C07D263/52 , C07D265/12 , C07D265/18 , C07D267/08 , C07D277/60 , C07D279/00 , C07D471/04 , C07D521/00 , C07F9/6561
CPC classification number: C07D243/24
-
公开(公告)号:DE19653647A1
公开(公告)日:1998-06-25
申请号:DE19653647
申请日:1996-12-20
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS-ULRICH DR , PEYMAN ANUSCHIRWAN DR , KNOLLE JOCHEN DR , RUXER JEAN-MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN-MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: C07D239/00 , A61K31/155 , A61K31/16 , A61K31/18 , A61K31/33 , A61K31/395 , A61K31/415 , A61K31/4184 , A61K31/47 , A61K31/472 , A61K31/55 , A61K38/04 , A61P9/00 , A61P19/08 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C279/20 , C07C279/24 , C07C311/64 , C07C313/30 , C07C327/00 , C07D217/24 , C07D233/04 , C07D235/16 , C07D243/06 , C07D253/06 , C07D253/08 , C07D263/52 , C07D267/08 , C07D277/60 , C07D471/02 , C07D471/04 , C07D487/04 , C07K5/04 , C07D487/08 , A61K38/39
Abstract: Guanidine and cycloguanidine derivatives of formula A-B-D-E-F-G (I) and their salts are new. A = R R N-C(=NR )NR Z- or a group of formula (a) or (b); Z = C(Q) or S(O)n; Q = O or S; n = 1 or 2; R = 5-10 membered mono- or polycyclic, aromatic or non-aromatic ring (optionally containing 1-4 N, O and/or S and optionally substituted by 1 or more of R -R ); B = direct bond; or alkyl, -CR =CR -, 5-10C aryl, 3-8C cycloalkyl or -C IDENTICAL C- (all optionally mono- or disubstituted by 1-8C alkyl), e.g. Me-Ph-Me or Et-CH=CH-; D, F = direct bond or alkyl, 5-10C aryl, -Q-; -NR -, -CO-NR -, -NR -CO-, -NR -C(Q)-NR -, -O-C(O)-,-C(O)-O-, -C(Q)-, -S(O)n, -S(O)n-NR , -NR -S(O)n, -CR =CR -, -C IDENTICAL C-, -NR -N=CR -, -N=CR -, -R C=N- or -CH(OH)- (all optionally mono- or disubstituted by alkyl, -CR -CR - or 5-6C aryl), e.g. Me-Ph-CH=CH- or Et-O-, and D is optionally linked to B via one of these substituents; E = template of a fibrinogen receptor antagonist; G = -CR R -(CR R )p-(CH2)p-R ; R , R = H; 1-10C alkyl (optionally substituted by 1 or more F); cycloalkyl; cycloalkyl-alkyl; aryl; aryl-alkyl; R OC(O)R ; R R NC(O)R ; or R C(O)R ; R -R = H; F; OH; alkyl; cycloalkyl; cycloalkyl-alkyl; R QR ; R CO2R ; R OC(O)R ; R -5-14C aryl-R ; R N(R )R ; R R NR ; R N(R )CO(O)R ; R S(O)n-N(R )R ; R QC(O)N(R )R ; R C(O)N(R )R ; R N(R )C(O)N(R )R ; R N(R )S(O)N(R )R ; R S(O)nR ; R C(O)R ; R N(R )C(O)R ; or R N(R )S(O)nR ; R = H; Alk; cycloalkyl; cycloalkyl-Alk; aryl; or aryl-Alk; Alk = alkyl (optionally substituted by 1 or more F); R = direct bond or alkyl; R = C(Q)R ; S(O)n-NR ; P(O)nR ; or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S, e.g. tetrazolyl, imidazolyl, pyrazolyl, oxazolyl or thiadiazolyl; R = OH; alkoxy; aryl-alkoxy; aryloxy; alkylcarbonyloxy-(1-4C) alkoxy; aryl-alkylcarbonyloxy-(1-6C) alkoxy; NH2; NH(alkyl); N(alkyl)2; aryl-alkylamino; dialkylaminocarbonylmethoxy; aryl- dialkylaminocarbonylmethoxy; arylamino; or a L- or D-aminoacid; R -R = H; 1-10C alkyl (optionally substituted by one or more F); 3-12C cycloalkyl; 3-12C cycloalkyl-alkyl; aryl; aryl-alkyl; NH2; R ONR ; R OR ; R OC(O)R ; R R NR ; R -aryl-R ; HO-alkyl-N(R )R ; R N(R )C(O)R ; R C(O)N(R )R ; R C(O)R ; R R N-C(=NR )-NR ; R R N-C(=NR ); or Q; or two adjacent R R substituents form -O-(CH2)n-O- or -OC(CH3)2O-; p, q = 0 or 1; alkyl moieties have 1-8C, cycloalkyl moieties 3-14C and aryl moieties 5-14C unless specified otherwise; compounds where E is a 6-membered aromatic ring (optionally containing 1-4 N and/or 1-4 substituents ) and the compound 4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine are excluded.
-
公开(公告)号:CZ234397A3
公开(公告)日:1998-03-18
申请号:CZ234397
申请日:1997-07-22
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , STILZ HANS ULRICH DR , GOURVEST JEAN FRANCOIS DR , CARNIATO DENIS DR , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR , PITTI ROBERT MAURICE , BODARY SARAH CATHERINE DR
IPC: C07C229/04 , A61K31/155 , A61K31/197 , A61K31/27 , A61K31/415 , A61K31/445 , A61K31/505 , A61P9/00 , A61P13/02 , A61P15/00 , A61P19/00 , A61P19/08 , A61P19/10 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C251/02 , C07C279/20 , C07C333/00 , C07D233/48 , C07D233/54 , C07D239/16 , C07D239/72 , C07D239/84 , C07D257/04 , C07D211/18 , A61K31/19
Abstract: Substituted cycloalkanes of formula R YABDEF'C(R )(R )(CH2)qR (I) and their salts are new. A = bond, 1-8C alkanediyl, NR C(Q)NR , NR C(Q)Q, NR S(O)nNR , NR S(O)nO, NR S(O)n, 3-12C cycloalkanediyl, C IDENTICAL C, NR CO, CONR , 5-14C arylene-CONR , O, S(O)n, 5-14C arylene, CO, 5-14C arylene-CO, NR , SO2NR , CO2, CR =CR or 5-14C arylene-S(O)n (all optionally mono- or disubstituted by 1-8C alkanediyl (sic), e.g. -1-8C alkanediyl-CONR -1-8C alkanediyl, 1-8C alkanediyl-CONR or CONR -1-8C alkanediyl); Q = O or S; B = bond, 1-10C alkanediyl, CR =CR or C IDENTICAL C (all optionally mono- or disubstituted by 1-8C alkanediyl); D, F' = bond, 1-8C alkanediyl, or Q, NR , CONR , NR CO, NR C(Q)NR , OCO, COO, CQ, S(O)n, S(O)2NR , NR S(O)n, CR =CR , C IDENTICAL C or CH(OH) (all optionally mono- or disubstituted by 1-8C alkanediyl); E = 6-membered aromatic group optionally containing 1-4 N atoms and optionally mono- to tetra-substituted by R , R , F, Cl, Br, I, NO2 and OH; Y = bond or NR ; R = NR C(=NR )R , C(=NR )NR R , NR C(=NR )NR R or a 4-10 membered monocyclic or polycyclic aromatic or non-aromatic ring optionally containing 1-4 N, O and/or S atoms and optionally substituted by 1 or more R , R , R and R ; R , R = H, 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkanediyl, 5-14C aryl, 5-14C aryl-1-8C alkanediyl, NH2, R N(R )OR , R OR , R COOR , R -5-14C arylene-R , R NR R , R NR -1-8C hydroxyalkyl, R CONR R , R NR C(O)R , R COR , C(=NR )NR R or 1-18C alkylcarbonyloxy-1-6C alkanediyloxycarbonyl; R = R QR , R OCOR , R COOR , R -5-14C arylene-R , R NR R , R NR R , R OCONR R , R NR S(O)nR , R NR COQR , R NR C(O)R , R N(R )C(O)N(R )R , R N(R )S(O)nN(R )R , R S(O)nR , R C(O)R , R CONR R , R S(O)nNR R , Cy or 1-8C alkyl substituted by Cy; Cy = monocyclic or polycyclic, saturated or mono- or poly-unsaturated 10-18C cycloalkyl optionally substituted by 1 or more Z'; Z' = 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkanediyl, 5-14C aryl, 5-14C aryl-1-8C alkanediyl, 1-8C alkoxy, 5-14C aryl-1-8C alkanediyloxy, 5-14C aryloxy, 1-8C alkylcarbonyloxy-1-4C alkanediyloxy, NH2, NH(1-8C alkyl), N(1-8C alkyl)2, 5-14C aryl-1-8C alkanediylamino, 5-14C arylamino, =Q, NO2, OH, F, Cl, Br or I; R = H, F, 1-8C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkanediyl, 5-14C aryl or 5-14C aryl-1-8C alkanediyl; R = Cy or 1-8C alkyl substituted by Cy; R = bond or 1-8C alkanediyl; R = H, 1-8C alkyl (optionally substituted by 1 or more F, or one 3-12C cycloalkyl or 5-14C aryl), 3-12C cycloalkyl or 5-14C aryl; R = C(Q)R , S(O)nR , P(O)(R )n or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S atoms; R = OH, 1-8C alkoxy(optionally substituted by 5-14C-aryl), 5-14C aryloxy, 1-8C alkylcarbonyloxy-1-4C alkanediyloxy, 5-14C aryl-1-8C alkanediylcarbonyloxy-1-6C alkanediyloxy, NH2, mono- or di- 1-8C alkylamino, 5-14C aryl-1-8C alkanediylamino, 1-8C dialkylaminocarbonylmethyleneoxy, 5-14C aryl-1-8C dialkylaminocarbonylmethyleneoxy, 5-14C arylamino or the residue of a L- or D-amino acid; R -R = H, 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkanediyl, 5-14C aryl, 5-14C aryl-1-8C alkanediyl, NH2, R N(R )OR , R OR , R COOR , R NR R , R NR -1-8C hydroxyalkyl, R CONR R , R COR , NR C(=NR )NR R , C(=NR )NR R , R -5-14C arylene-R , R NR COR or Q; n = 1 or 2; q = 0 or 1.
-
公开(公告)号:ID19253A
公开(公告)日:1998-06-28
申请号:ID973918
申请日:1997-12-18
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS ULRICH DR , PEYMAN ANUSCHIRWAN DR , KNOLLE JOCHEN DR , RUXER JEAN MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: A61K31/155 , A61K31/16 , A61K31/18 , A61K31/33 , A61K31/395 , A61K31/415 , A61K31/4184 , C07D239/00 , A61K31/47 , A61K31/472 , A61K31/55 , A61K38/04 , A61P9/00 , A61P19/08 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C279/20 , C07C279/24 , C07C311/64 , C07C313/30 , C07C327/00 , C07D217/24 , C07D233/04 , C07D235/16 , C07D243/06 , C07D253/06 , C07D253/08 , C07D263/52 , C07D267/08 , C07D277/60 , C07D471/02 , C07D471/04 , C07D487/04 , C07K5/04 , C07K5/08 , A61K38/00 , A61K39/00 , A61K31/00 , C07D401/02 , C07D519/00
Abstract: Guanidine and cycloguanidine derivatives of formula A-B-D-E-F-G (I) and their salts are new. A = R R N-C(=NR )NR Z- or a group of formula (a) or (b); Z = C(Q) or S(O)n; Q = O or S; n = 1 or 2; R = 5-10 membered mono- or polycyclic, aromatic or non-aromatic ring (optionally containing 1-4 N, O and/or S and optionally substituted by 1 or more of R -R ); B = direct bond; or alkyl, -CR =CR -, 5-10C aryl, 3-8C cycloalkyl or -C IDENTICAL C- (all optionally mono- or disubstituted by 1-8C alkyl), e.g. Me-Ph-Me or Et-CH=CH-; D, F = direct bond or alkyl, 5-10C aryl, -Q-; -NR -, -CO-NR -, -NR -CO-, -NR -C(Q)-NR -, -O-C(O)-,-C(O)-O-, -C(Q)-, -S(O)n, -S(O)n-NR , -NR -S(O)n, -CR =CR -, -C IDENTICAL C-, -NR -N=CR -, -N=CR -, -R C=N- or -CH(OH)- (all optionally mono- or disubstituted by alkyl, -CR -CR - or 5-6C aryl), e.g. Me-Ph-CH=CH- or Et-O-, and D is optionally linked to B via one of these substituents; E = template of a fibrinogen receptor antagonist; G = -CR R -(CR R )p-(CH2)p-R ; R , R = H; 1-10C alkyl (optionally substituted by 1 or more F); cycloalkyl; cycloalkyl-alkyl; aryl; aryl-alkyl; R OC(O)R ; R R NC(O)R ; or R C(O)R ; R -R = H; F; OH; alkyl; cycloalkyl; cycloalkyl-alkyl; R QR ; R CO2R ; R OC(O)R ; R -5-14C aryl-R ; R N(R )R ; R R NR ; R N(R )CO(O)R ; R S(O)n-N(R )R ; R QC(O)N(R )R ; R C(O)N(R )R ; R N(R )C(O)N(R )R ; R N(R )S(O)N(R )R ; R S(O)nR ; R C(O)R ; R N(R )C(O)R ; or R N(R )S(O)nR ; R = H; Alk; cycloalkyl; cycloalkyl-Alk; aryl; or aryl-Alk; Alk = alkyl (optionally substituted by 1 or more F); R = direct bond or alkyl; R = C(Q)R ; S(O)n-NR ; P(O)nR ; or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S, e.g. tetrazolyl, imidazolyl, pyrazolyl, oxazolyl or thiadiazolyl; R = OH; alkoxy; aryl-alkoxy; aryloxy; alkylcarbonyloxy-(1-4C) alkoxy; aryl-alkylcarbonyloxy-(1-6C) alkoxy; NH2; NH(alkyl); N(alkyl)2; aryl-alkylamino; dialkylaminocarbonylmethoxy; aryl- dialkylaminocarbonylmethoxy; arylamino; or a L- or D-aminoacid; R -R = H; 1-10C alkyl (optionally substituted by one or more F); 3-12C cycloalkyl; 3-12C cycloalkyl-alkyl; aryl; aryl-alkyl; NH2; R ONR ; R OR ; R OC(O)R ; R R NR ; R -aryl-R ; HO-alkyl-N(R )R ; R N(R )C(O)R ; R C(O)N(R )R ; R C(O)R ; R R N-C(=NR )-NR ; R R N-C(=NR ); or Q; or two adjacent R R substituents form -O-(CH2)n-O- or -OC(CH3)2O-; p, q = 0 or 1; alkyl moieties have 1-8C, cycloalkyl moieties 3-14C and aryl moieties 5-14C unless specified otherwise; compounds where E is a 6-membered aromatic ring (optionally containing 1-4 N and/or 1-4 substituents ) and the compound 4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine are excluded.
-
9.
公开(公告)号:CZ9702344A3
公开(公告)日:1998-03-18
申请号:CZ234497
申请日:1997-07-22
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , STILZ HANS ULRICH DR , GOURVEST JEAN FRANCOIS DR , CARNIATO DENIS DR , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR , PITTI ROBERT MAURICE , BODARY SARAH CATHERINE DR
IPC: C07C229/04 , A61K31/19 , A61K31/197 , A61K31/415 , A61K31/445 , A61P3/00 , A61P9/00 , A61P13/02 , A61P15/00 , A61P19/08 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C251/02 , C07D211/18 , C07D233/52 , C07D233/54 , C07D233/66 , C07D257/04
CPC classification number: C07D233/52
-
10.
公开(公告)号:CZ234497A3
公开(公告)日:1998-03-18
申请号:CZ234497
申请日:1997-07-22
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , STILZ HANS ULRICH DR , GOURVEST JEAN FRANCOIS DR , CARNIATO DENIS DR , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR , PITTI ROBERT MAURICE , BODARY SARAH CATHERINE DR
IPC: C07C229/04 , A61K31/19 , A61K31/197 , A61K31/415 , A61K31/445 , A61P3/00 , A61P9/00 , A61P13/02 , A61P15/00 , A61P19/08 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C251/02 , C07D211/18 , C07D233/52 , C07D233/54 , C07D233/66 , C07D257/04
Abstract: Aromatic compounds of formula R1YABDEF'CR R R )p(CH2)q-R (I) and their salts are new. A = bond, Z, 1-8C alkanediyl, NR C(Q)NR , NR C(Q)Q, NR S(O)nNR , NR S(O)nO, NR -S(O)n, 3-12C cycloalkanediyl, C IDENTICAL C, NR C(O), C(O)NR , 5-14C arylene-C(O)NR , O, S(O)n, 5-14C arylene, CO, 5-14C arylene-CO, NR , SO2NR , CO2, CR =CR or 5-14C arylene-S(O)n (all optionally mono- or disubstituted by 1-8C alkanediyl, i.e. e.g. 1-8C alkanediyl-CONR -1-8C alkanediyl, 1-8C alkanediyl-CONR or CONR -1-8C alkanediyl); Z = NR -N=CR , N=CR or CR =N; Q = O or S; B = direct bond, 1-8C alkanediyl, CR =CR or C IDENTICAL C (all optionally mono- or disubstituted by 1-8C alkanediyl) or a divalent residue of a 5- or 6-membered saturated or unsaturated ring containing 1 or 2 N atoms (optionally mono- or disubstituted by 1-6C alkyl or Q); D, F' = bond, 1-8C alkanediyl, or Z, Q, NR , CONR , NR CO, NR C(Q)NR , OC(O), C(O)O, CQ, S(O), S(O)2, S(O)2NR , NR S(O), NR S(O)2, CR =CR , C IDENTICAL C or CH(OH) (all optionally mono- or disubstituted by 1-8C alkanediyl); E = 6-membered aromatic group optionally containing 1-4 N atoms (optionally mono- to tetra-substituted by R , R , F, Cl, Br, I, NO2 and OH); Y = bond or NR ; R = NR CR ), C(=NR )NR R , NR C(=NR )NR R , or a 4-10 membered monocyclic or polycyclic aromatic or non-aromatic ring optionally containing 1-4 N, O and/or S atoms (optionally substituted by 1 or more R -R ); R , R = H, 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-(1-8C)alkanediyl, 5-14C aryl, 5-14C aryl-(1-8C)alkanediyl, NH2, R NR OR , R OR , R COOR , R -5-14C arylene-R , R N(R )2, R NR 1-8C alkanediyl-OH, R CON(R )2, R NR C(O)R , R C(O)R , C(=NR )N(R )2 or (1-18C)alkylcarbonyloxy(1-6)alkanediyloxycarbonyl; R -R = H, F, OH, 1-8C alkyl, 3-12C cycloalkyl, 3-12C-cycloalkyl(1-8C)alkanediyl, R QR , R OCOR , R COOR , R -5-14C arylene-R , etc.; R = H, 1-8C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 1-8C-alkanediyl-3-12C cycloalkyl, 5-14C aryl or 1-8C alkanediyl-5-14C aryl; R = direct bond or 1-8C alkanediyl; R = C(Q)R , S(O)nR , P(O)(R )n or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S atoms; R = OH, 1-8C alkoxy, 1-8C alkanediyl-5-14C-aryl, 5-14C aryloxy, 1-4C alkanediyloxycarbonyl1-8C alkylcarbonyloxy, 5-14C aryl-1-8C alkanediylcarbonyloxy-1-6C alkanediyloxy, NH2, NH(1-8C alkyl), N(1-8C alkyl)2, 5-14C aryl-1-8C alkanediylamino, 1-8C dialkylaminocarbonylmethyleneoxy, 5-14C aryl-1-8C dialkylaminocarbonylmethyleneoxy, 5-14C arylamino or the residue of a L- or D-amino acid; R -R = H, 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, etc.; n = 1 or 2; p, q = 0 or 1; provided that at least 1 of A, D and F' = Z.
-
-
-
-
-
-
-
-
-